Venous Limb Gangrene during Warfarin Treatment of Cancer-Associated Deep Venous Thrombosis
Author:
- 16 October 2001
- journal article
- case report
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 135 (8_Part_1) , 589-593
Abstract
The cause of cancer-associated venous limb gangrene is unknown but could paradoxically be due to warfarin. To determine the pathogenesis of venous gangrene in a patient with cancer. Case report. University hospital in Ontario, Canada. 66-year-old woman with metastatic lung cancer and deep venous thrombosis. Levels of vitamin K–dependent factors, additional coagulation factors, and thrombin–antithrombin complexes (marker of thrombin generation). During warfarin use, venous limb gangrene developed when the international normalized ratio (INR) reached 6.0 (therapeutic range, 2.0 to 3.0); at this time, the level of protein C (a vitamin K–dependent natural anticoagulant) was severely reduced, but thrombin–antithrombin complexes remained markedly elevated. The supratherapeutic INR was explained by the greatly reduced levels of factor VII, which correlated closely with protein C levels; therefore, the high INR was a surrogate marker for severely reduced protein C activity. Warfarin may contribute to the pathogenesis of cancer-associated venous limb gangrene by leading to severe depletion of protein C while at the same time failing to reduce thrombin generation.Keywords
This publication has 18 references indexed in Scilit:
- Laboratory Testing for Heparin-Induced ThrombocytopeniaJournal of Thrombosis and Thrombolysis, 2000
- Regulation of blood coagulationBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2000
- Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopeniaAmerican Journal of Hematology, 1999
- Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: a comparison with standard platelet agonistsPlatelets, 1999
- Occult cancer in patients with bilateral deep-vein thrombosisThe Lancet, 1997
- Studies on tumor-cell-induced platelet aggregation in human lung cancer cell linesJournal of Cancer Research and Clinical Oncology, 1996
- Extrinsic-pathway activation in cancer with high factor Vlla and tissue factorThe Lancet, 1995
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinNew England Journal of Medicine, 1995
- Immune Endothelial-Cell Injury in Heparin-Associated ThrombocytopeniaNew England Journal of Medicine, 1987
- Trousseau's syndrome. Devastating coagulopathy in the absence of heparinThe American Journal of Medicine, 1985